NICE says Bayer’s liver cancer drug is not cost-effective
The National Institute for Health and Care Excellence (NICE) has released draft guidance that liver cancer drug sorafenib (Nexavar, Bayer) – which is currently available on the Cancer Drugs Fund (CDF) – is not value for money.
Click on this link for more information.
